Abstracts Archive - Page 2428 of 2605 - ACR Meeting Abstracts

Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting
Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Helga Radner¹, Farideh Alasti², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…
Abstract Number: 2609 • 2012 ACR/ARHP Annual Meeting
Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Aatke van der Maas¹, Elisabeth Lie², Robin Christensen³, Ernest Choy⁴, Yaël A. de Man⁵, Piet L.C.M. van Riel⁶, Thasia G. Woodworth⁷ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Medicine, Division of Rheumatology, Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: To enable consistent assessment of impact of tapering, withdrawal and dose optimization strategies, there is an increasing need for validated measures of flare in…
Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting
Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort
Bindee Kuriya¹, Juan Xiong², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Diane Tin⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰ and CATCH¹¹, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Dr. Vivian P. Bykerk, Toronto, ON, Canada
Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…
Abstract Number: 2611 • 2012 ACR/ARHP Annual Meeting
Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To determine if demographic and disease characteristics of patients with PsA at presentation to a PsA clinic cluster into distinct groups. Methods: 1058 patients…
Abstract Number: 2612 • 2012 ACR/ARHP Annual Meeting
Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a 3-Month Period?
Manouk de Hooge¹, Rosaline van den Berg¹, Monique Reijnierse², Victoria Navarro-Compán¹, Floris van Gaalen¹, Tom Huizinga¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: A positive MRI at baseline is a strong predictor for a positive follow-up MRI1. But many questions about the volatility of the lesions over…
Abstract Number: 2613 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Philip J. Mease¹, Roy Fleischmann², Jürgen Wollenhaupt³, Atul A. Deodhar⁴, Danuta Kielar⁵, Franz Woltering⁶, Christian Stach⁶, Bengt Hoepken⁶, Terri Arledge⁷ and Désirée van der Heijde⁸, ¹Seattle Rheumatology Associates, Seattle, WA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Schön-Klinik, Hamburg, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rheim, Germany, ⁷UCB Pharma, Rtp, NC, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has shown efficacy in reducing signs and symptoms of psoriatic arthritis (PsA).1 RAPID-PsA (NCT01087788) is the first…
Abstract Number: 2614 • 2012 ACR/ARHP Annual Meeting
The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis
Maureen Dubreuil¹, Young Hee Rho², Ada Man¹, Yanyan Zhu³, Yuqing Zhang², Thorvardur Love⁴, Alexis Ogdie⁵, Joel Gelfand⁶ and Hyon Choi⁷, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Department of Biostatistics, Boston University School of Public Health, Department of Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Landspitali University Hospital, Reykjavik, Iceland, ⁵Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania., Philadelphia, PA, ⁷Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The potential impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on the risk of incident diabetes remains unclear. Studies have shown that patients…
Abstract Number: 2615 • 2012 ACR/ARHP Annual Meeting
Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination
Anne C. Bay-Jensen¹, Morten Asser Karsdal², Efstathios Vassiliadis³, Stephanie Wichuk⁴, Zheng Zhao⁵, Robert GW Lambert⁶, Rik Lories⁷, Claus Christiansen⁸ and Walter P. Maksymowych⁹, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁶Radiology, University of Alberta, Edmonton, AB, Canada, ⁷Laboratory of Tissue Homeostasis and Disease - SBE Research Center, KU Leuven, Leuven, Belgium, ⁸CCBR, Ballerup, Denmark, ⁹Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis (RA) is considered an anti-CCP positive disease whereas ankylosing spondylitis (AS) is considered an anti-CCP negative disease. Anti-CCP has prognostic capacity in…
Abstract Number: 2616 • 2012 ACR/ARHP Annual Meeting
The Transition From Psoriasis (Ps) to Psoriatic Arthritis (PsA) Is Associated with Elevated Circulating Osteoclast Precursors (OCP) and Increased Expression of DC-STAMP
Ya-Hui Chiu¹, Edward M. Schwarz², Dafna D. Gladman³, Sharon Moorehead⁴, Michelle Smith⁴, Rick Barrett⁴ and Christopher T. Ritchlin⁴, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 20% of psoriasis (Ps) patients (pts) develop psoriatic arthritis (PsA). Early diagnosis and therapy of PsA can limit bone and joint damage; however,…
Abstract Number: 2617 • 2012 ACR/ARHP Annual Meeting
Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States
Christopher E. Collins¹, Siva Narayanan², Maria Dall'era³, Greg Dennis⁴, Alan Oglesby⁵, Mark B. McGuire⁶, Ramesh Pappu⁷, Charles T. Molta⁸ and Greg Keenan⁴, ¹Rheumatology, Washington Hospital Ctr, Washington, DC, ²Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Human Genome Sciences, Inc., Rockville, MD, ⁵GlaxoSmithKline, Research Triangle Park, NC, ⁶Medical Data Analytics, Parsippany, NJ, ⁷GlaxoSmithKline, USA, Philadelphia, PA, ⁸GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Effectiveness of belimumab in black/African American (AA) patients (pts) with Systemic Lupus Erythematous (SLE) is yet to be adequately demonstrated. The objective of this…
Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting
Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy
Eduardo F. Borba¹, Sandra G. Pasoto¹, Ana L. Calich¹, Ricardo Fuller¹, Vilma S.T. Viana¹, Margareth Vendramini¹, Joao Miraglia², Maria A. Ishida³ and Eloisa Bonfa⁴, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ³Instituto Adolfo Lutz, São Paulo, Brazil, ⁴Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
Abstract Number: 2619 • 2012 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Cynthia Aranow¹, Maria Dall'era², Elena M. Massarotti³, Meggan C. Mackay⁴, Andreea Coca⁵, Fotios Koumpouras⁶, Marc C. Levesque⁷, W. Winn Chatham⁸, Megan E. B. Clowse⁹, Lisa G. Criscione-Schreiber¹⁰, Sherri Callahan¹¹, Ellen A. Goldmuntz¹², Lynette Keyes-Elstein¹³, Betty Diamond¹⁴ and Diane L. Kamen¹⁵, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁶Lupus Center of Excellence, West Penn Hospital, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Rheumatology, Duke University Health System, Durham, NC, ¹¹Dait, NIAID/NIH Rm 6807, Bethesda, MD, ¹²DAIT, NIAID/NIH, Bethesda, MD, ¹³Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ¹⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Exposure of normal PBMCs to1,25 OH vitamin D reverses the stimulatory effects of activating SLE sera on the interferon signature. Given that IFN is…
Abstract Number: 2620 • 2012 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE
Robert Zimmer¹, Daniel J. Wallace² and Sylviane Muller³, ¹ImmuPharma France, Mulhouse, France, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France
Background/Purpose: Advances in the understanding of autoimmune diseases pathogenesis have led to the development of peptide-based therapies that aim to potentially reinstate tolerance to self…
Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting
Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients
Joan T. Merrill¹, Richard A. Furie², Daniel J. Wallace³, William Stohl⁴, W. Winn Chatham⁵, Arthur Weinstein⁶, James D. McKay, Ellen M. Ginzler⁸, Z. John Zhong⁹, William W. Freimuth⁹ and Michelle Petri¹⁰, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²North Shore-LIJ Health System, Lake Success, NY, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Washington Hospital Center, Washington, DC, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ⁸Human Genome Sciences, Inc., Rockville, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE. Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
Abstract Number: 2622 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
K. Kalunian¹, Joan T. Merrill², R. Maciuca³, Wenjun Ouyang³, J. M. McBride³, Michael J. Townsend³, E. Park³, J. Li³, X. Wei³, A. Morimoto³, R. Boismenu³, John C. Davis Jr.³ and William P. Kennedy³, ¹UCSD School of Medicine, La Jolla, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Genentech, Inc, South San Francisco, CA
Background/Purpose: Dysregulation of interferon alpha (IFN) activity and/or signaling is implicated in systemic lupus (SLE). This randomized, double-blind, placebo-controlled, two part Phase 2 study (ROSE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].